Deferitrin (GT56-252) + desferoxamine (DFO)
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Beta-Thalassemia
Conditions
Beta-Thalassemia
Trial Timeline
Sep 1, 2003 → Nov 1, 2005
NCT ID
NCT00069862About Deferitrin (GT56-252) + desferoxamine (DFO)
Deferitrin (GT56-252) + desferoxamine (DFO) is a phase 1/2 stage product being developed by Sanofi for Beta-Thalassemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00069862. Target conditions include Beta-Thalassemia.
What happened to similar drugs?
2 of 7 similar drugs in Beta-Thalassemia were approved
Approved (2) Terminated (0) Active (5)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00069862 | Phase 1/2 | Completed |
Competing Products
18 competing products in Beta-Thalassemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ACE-536 | Merck | Phase 2 | 42 |
| Deferasirox | Novartis | Approved | 43 |
| Zoledronic acid + Placebo | Novartis | Phase 2/3 | 34 |
| deferasirox | Novartis | Phase 3 | 40 |
| ICL670 + deferoxamine | Novartis | Phase 3 | 40 |
| Deferasirox | Novartis | Phase 2 | 35 |
| Deferasirox | Novartis | Phase 2 | 35 |
| ICL670 | Novartis | Approved | 43 |
| Bitopertin | Roche | Phase 2 | 35 |
| Luspatercept + Placebo | Bristol Myers Squibb | Phase 2 | 39 |
| CTX001 | Vertex Pharmaceuticals | Phase 3 | 44 |
| CTX001 | Vertex Pharmaceuticals | Phase 3 | 47 |
| CTX001 | Vertex Pharmaceuticals | Phase 2/3 | 38 |
| CTX001 | Vertex Pharmaceuticals | Phase 3 | 47 |
| Mozobil + Mozobil + Mozobil | Sanofi | Pre-clinical | 26 |
| REGN7999 + Placebo | Regeneron Pharmaceuticals | Phase 2 | 42 |
| VIT-2763 60 mg QD + VIT-2763 60 mg BID + VIT-2763 120 mg BID + Placebo | LabCorp | Phase 2 | 24 |
| VIT-2763 once a day (QD) + VIT-2763 twice a day (BID) + Placebo | LabCorp | Phase 2 | 32 |